Cytokinetics CEO plans $7.1M stock sale

Rule 144 notice registers a planned NASDAQ sale of 97,926 Cytokinetics common shares held by a trust for CEO Robert I. Blum.

Rhea-AI Filing Summary

CYTOKINETICS INC (CYTK) received a Rule 144 notice covering a proposed sale of common stock beneficially associated with President, CEO and Director Robert I. Blum. The notice relates to up to 97,926 shares of common stock, originally acquired from the issuer as equity compensation between December 2024 and March 2026.

The shares covered are stated to have been sold by the Bridget Blum 2026 Irrevocable Trust, with Robert I. Blum as trustee, and J.P. Morgan Securities LLC acting as agent and attorney-in-fact. The approximate aggregate market value listed for the securities to be sold is $7,094,739, with 139,023,418 shares of this class outstanding and an indicated sale date of September 15, 2026 on NASDAQ.

Key Figures

Shares covered by Rule 144 notice: 97,926 shares Approximate aggregate market value: $7,094,739 Shares outstanding of this class: 139,023,418 shares +2 more

5 metrics

Shares covered by Rule 144 notice 97,926 shares Cytokinetics common stock associated with Robert I. Blum

Approximate aggregate market value $7,094,739 Value of securities to be sold under Rule 144

Shares outstanding of this class 139,023,418 shares Cytokinetics common stock outstanding at time of notice

Proposed sale date September 15, 2026 Approximate date of sale for the covered shares

Date of notice September 15, 2026 Filing date of the Rule 144 notice

Key Terms

Rule 144, equity compensation, Irrevocable Trust, attorney-in-fact

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

equity compensation financial

"acquired from Issuer as equity compensation between December 2024 and March 2026"

Equity compensation is pay given to employees, executives or contractors in the form of company ownership—such as stock, stock options or restricted shares—rather than just cash. It matters to investors because it can align workers' incentives with shareholders (like paying someone in slices of the same pie they help grow), but it also increases the number of shares outstanding and company expenses, affecting ownership percentages and earnings per share.

Irrevocable Trust financial

"The shares covered by this filing were sold by the Bridget Blum 2026 Irrevocable Trust"

An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.

attorney-in-fact regulatory

"J.P. Morgan Securities LLC as agent and attorney-in-fact for Robert I. Blum"

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for CYTK?

It discloses a planned Rule 144 sale of 97,926 shares of Cytokinetics common stock associated with President and CEO Robert I. Blum, held in the Bridget Blum 2026 Irrevocable Trust, with an indicated sale date of September 15, 2026 on NASDAQ.

Who is selling Cytokinetics (CYTK) shares under this Rule 144 notice?

The filing states the shares covered were sold by the Bridget Blum 2026 Irrevocable Trust, with Robert I. Blum serving as trustee. J.P. Morgan Securities LLC signed the notice as agent and attorney-in-fact for Robert I. Blum.

How many CYTK shares are covered and what is their market value?

The notice covers 97,926 shares of Cytokinetics common stock with an approximate aggregate market value of $7,094,739. The class of securities has 139,023,418 shares outstanding according to the disclosure.

When were the CYTK shares being sold originally acquired?

The shares were acquired from Cytokinetics as equity compensation between December 2024 and March 2026, according to the Rule 144 disclosure describing the nature and timing of acquisition.

What trading venue and timing are indicated for the CYTK Rule 144 sale?

The filing lists NASDAQ as the securities exchange and indicates an approximate sale date of September 15, 2026 for the 97,926 Cytokinetics common shares covered by the notice.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/15/2026 - 05:51 PM Accepted by SEC EDGAR 09/15/2026 - 05:51 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001288859
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Cytokinetics, Inc.
SEC File Number	000-50633
Address of Issuer	350 Oyster Point Boulevard South San Francisco CALIFORNIA 94080
Phone	650-624-3000
Name of Person for Whose Account the Securities are To Be Sold	Robert I. Blum
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	President, CEO, Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	J.P. Morgan Securities LLC 270 Park Avenue, 10th Floor New York NY 10017	97926	7094739	139023418	09/15/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	09/14/2026	Transfer	Robert Blum, who acquired from Issuer as equity compensation between December 2024 and March 2026			97926	09/14/2026	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	The shares covered by this filing were sold by the Bridget Blum 2026 Irrevocable Trust, Robert I. Blum as Trustee
Date of Notice	09/15/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ J.P. Morgan Securities LLC as agent and attorney-in-fact for Robert I. Blum
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)